List view / Grid view
AstraZeneca reported on the remuneration arrangements relating to David Brennan’s…
16 July 2012 | By AstraZeneca
AstraZeneca reported on the remuneration arrangements relating to David Brennan’s retirement...
As AstraZeneca PLC Chief Executive David Brennan steps down...
27 April 2012 | By AstraZeneca
As AstraZeneca PLC Chief Executive David Brennan steps down...
AstraZeneca announced that Chief Executive Officer and Board member, David…
26 April 2012 | By AstraZeneca
AstraZeneca announced that Chief Executive Officer and Board member, David Brennan has decided to retire...
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3…
2 April 2012 | By Amgen
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...
AstraZeneca has announced new restructuring initiatives designed to improve productivity…
2 February 2012 | By AstraZeneca
AstraZeneca has announced new restructuring initiatives designed to improve productivity and strengthen the company’s capabilities...
A wide range of compounds will be made available FOC…
5 December 2011 | By AstraZeneca
A wide range of compounds will be made available FOC to UK medical researchers...
The US FDA has approved BRILINTA (ticagrelor) tablets...
20 July 2011 | By AstraZeneca
The US FDA has approved BRILINTA (ticagrelor) tablets...
AstraZeneca has agreed to sell its Astra Tech business to…
22 June 2011 | By AstraZeneca
AstraZeneca has agreed to sell its Astra Tech business to DENTSPLY for approximately $1.8 billion in cash...
AstraZeneca plans to establish a Predictive Science Centre in St.…
16 June 2011 | By AstraZeneca
AstraZeneca plans to establish a Predictive Science Centre in St. Petersburg...
AstraZeneca announced today that the European Commission has granted marketing…
6 December 2010 | By AstraZeneca
AstraZeneca announced today that the European Commission has granted marketing authorisation to BRILIQUE™ (ticagrelor tablets)...
AstraZeneca announced today that Judge Joseph Farnan, Jr., US District…
30 June 2010 | By AstraZeneca
AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the ‘314 patent) is valid and enforceable...
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a…
28 June 2010 | By AstraZeneca
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria...
